Emmaus Life Sciences, Inc. (EMMA)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.54 Million USD | 153.75% |
| 2022 | -6.58 Million USD | -7.47% |
| 2021 | -6.12 Million USD | -14151.16% |
| 2020 | -43 Thousand USD | 99.05% |
| 2019 | -4.51 Million USD | 55.96% |
| 2018 | -10.24 Million USD | -44.22% |
| 2017 | -7.1 Million USD | -88.58% |
| 2016 | -3.76 Million USD | -41.8% |
| 2015 | -2.65 Million USD | 30.4% |
| 2014 | -3.81 Million USD | 9.14% |
| 2013 | -4.2 Million USD | 12.59% |
| 2012 | -4.8 Million USD | 17.56% |
| 2011 | -5.82 Million USD | 10.39% |
| 2010 | -6.5 Million USD | 2.8% |
| 2009 | -6.69 Million USD | -22.25% |
| 2008 | -5.47 Million USD | -67.42% |
| 2007 | -3.26 Million USD | -685.57% |
| 2006 | -416.2 Thousand USD | -1356.35% |
| 2005 | -28.57 Thousand USD | 89.05% |
| 2004 | -261.08 Thousand USD | -88.34% |
| 2003 | -138.62 Thousand USD | -1236.18% |
| 2002 | -10.37 Thousand USD | -11.93% |
| 2001 | -9269.00 USD | -31.07% |
| 2000 | -7072.00 USD | 29.28% |
| 1999 | -10 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.74 Million USD | -302.21% |
| 2024 Q2 | 582 Thousand USD | 121.24% |
| 2023 Q4 | 1.35 Million USD | 5545.83% |
| 2023 Q2 | 3.32 Million USD | 385.49% |
| 2023 Q1 | -1.16 Million USD | 17.84% |
| 2023 FY | 3.54 Million USD | 153.75% |
| 2023 Q3 | 24 Thousand USD | -99.28% |
| 2022 Q3 | -660 Thousand USD | 54.17% |
| 2022 Q4 | -1.41 Million USD | -114.85% |
| 2022 FY | -6.58 Million USD | -7.47% |
| 2022 Q1 | -3.06 Million USD | 38.21% |
| 2022 Q2 | -1.44 Million USD | 53.06% |
| 2021 Q3 | -31 Thousand USD | -106.42% |
| 2021 Q2 | 483 Thousand USD | 129.91% |
| 2021 Q1 | -1.61 Million USD | -547.37% |
| 2021 FY | -6.12 Million USD | -14151.16% |
| 2021 Q4 | -4.96 Million USD | -15916.13% |
| 2020 Q2 | -1.53 Million USD | -235.36% |
| 2020 Q1 | 1.13 Million USD | 306.45% |
| 2020 Q3 | 8000.00 USD | 100.52% |
| 2020 Q4 | 361 Thousand USD | 4412.5% |
| 2020 FY | -43 Thousand USD | 99.05% |
| 2019 FY | -4.51 Million USD | 55.96% |
| 2019 Q2 | -2.7 Million USD | -0.69% |
| 2019 Q3 | -3.59 Million USD | -33.17% |
| 2019 Q1 | -2.68 Million USD | -0.09% |
| 2019 Q4 | 279 Thousand USD | 107.75% |
| 2018 Q4 | -2.68 Million USD | -38.02% |
| 2018 Q2 | -2.91 Million USD | -10.65% |
| 2018 Q1 | -2.63 Million USD | 4.45% |
| 2018 Q3 | -1.94 Million USD | 33.31% |
| 2018 FY | -10.24 Million USD | -44.22% |
| 2017 Q3 | -2.69 Million USD | -73.3% |
| 2017 Q1 | -1.42 Million USD | 1.11% |
| 2017 Q2 | -1.55 Million USD | -9.45% |
| 2017 Q4 | -2.75 Million USD | -2.31% |
| 2017 FY | -7.1 Million USD | -88.58% |
| 2016 Q1 | -690 Thousand USD | -10.77% |
| 2016 Q4 | -1.43 Million USD | 12.6% |
| 2016 Q3 | -1.64 Million USD | -103.03% |
| 2016 FY | -3.76 Million USD | -41.8% |
| 2016 Q2 | -809.2 Thousand USD | -17.28% |
| 2015 Q3 | -542.7 Thousand USD | 2.27% |
| 2015 Q1 | -779.2 Thousand USD | 0.0% |
| 2015 FY | -2.65 Million USD | 30.4% |
| 2015 Q4 | -622.9 Thousand USD | -14.78% |
| 2015 Q2 | -555.3 Thousand USD | 28.73% |
| 2014 FY | -3.81 Million USD | 9.14% |
| 2014 Q3 | -897.5 Thousand USD | 11.54% |
| 2014 Q4 | -779.2 Thousand USD | 13.18% |
| 2014 Q1 | -940.7 Thousand USD | 2.41% |
| 2014 Q2 | -1.01 Million USD | -7.86% |
| 2013 Q1 | -1.12 Million USD | -60.91% |
| 2013 FY | -4.2 Million USD | 12.59% |
| 2013 Q3 | -1.19 Million USD | -1.55% |
| 2013 Q4 | -963.9 Thousand USD | 19.52% |
| 2013 Q2 | -1.17 Million USD | -4.87% |
| 2012 Q4 | -698.9 Thousand USD | 0.89% |
| 2012 Q2 | -1.25 Million USD | 11.52% |
| 2012 FY | -4.8 Million USD | 17.56% |
| 2012 Q1 | -1.41 Million USD | 0.73% |
| 2012 Q3 | -705.2 Thousand USD | 43.79% |
| 2011 Q2 | -1.44 Million USD | 3.85% |
| 2011 FY | -5.82 Million USD | 10.39% |
| 2011 Q4 | -1.42 Million USD | -7.49% |
| 2011 Q1 | -1.5 Million USD | 2.4% |
| 2011 Q3 | -1.32 Million USD | 8.29% |
| 2010 Q2 | -1.45 Million USD | -4.83% |
| 2010 Q1 | -1.39 Million USD | 25.03% |
| 2010 FY | -6.5 Million USD | 2.8% |
| 2010 Q3 | -1.79 Million USD | -23.13% |
| 2010 Q4 | -1.54 Million USD | 14.06% |
| 2009 Q3 | -2.42 Million USD | -75.65% |
| 2009 Q4 | -1.85 Million USD | 23.39% |
| 2009 FY | -6.69 Million USD | -22.25% |
| 2009 Q1 | -1.45 Million USD | -1.59% |
| 2009 Q2 | -1.37 Million USD | 5.21% |
| 2008 Q2 | -1.6 Million USD | -20.19% |
| 2008 Q1 | -1.33 Million USD | -26.0% |
| 2008 Q4 | -1.43 Million USD | 2.23% |
| 2008 FY | -5.47 Million USD | -67.42% |
| 2008 Q3 | -1.46 Million USD | 8.87% |
| 2007 FY | -3.26 Million USD | -685.57% |
| 2007 Q4 | -1.06 Million USD | 32.78% |
| 2007 Q3 | -1.58 Million USD | -183.2% |
| 2007 Q1 | -1.33 Million USD | -2206.37% |
| 2007 Q2 | -557.9 Thousand USD | 58.28% |
| 2006 Q4 | -57.98 Thousand USD | 54.61% |
| 2006 Q3 | -127.73 Thousand USD | 43.47% |
| 2006 Q2 | -225.96 Thousand USD | -4893.68% |
| 2006 Q1 | -4525.00 USD | 68.98% |
| 2006 FY | -416.2 Thousand USD | -1356.35% |
| 2005 Q2 | 942.00 USD | 110.02% |
| 2005 FY | -28.57 Thousand USD | 89.05% |
| 2005 Q4 | -14.58 Thousand USD | -163.72% |
| 2005 Q3 | -5532.00 USD | -687.26% |
| 2005 Q1 | -9400.00 USD | 91.08% |
| 2004 Q4 | -105.33 Thousand USD | 26.6% |
| 2004 FY | -261.08 Thousand USD | -88.34% |
| 2004 Q1 | -2173.00 USD | 44.72% |
| 2004 Q3 | -143.51 Thousand USD | -457.67% |
| 2004 Q2 | -25.73 Thousand USD | -1084.26% |
| 2003 FY | -138.62 Thousand USD | -1236.18% |
| 2003 Q1 | -1776.00 USD | 55.11% |
| 2003 Q4 | -3931.00 USD | 93.19% |
| 2003 Q3 | -57.75 Thousand USD | 23.17% |
| 2003 Q2 | -75.17 Thousand USD | -4132.6% |
| 2002 Q1 | -2570.00 USD | 20.58% |
| 2002 FY | -10.37 Thousand USD | -11.93% |
| 2002 Q4 | -3956.00 USD | -148.65% |
| 2002 Q3 | -1591.00 USD | 29.54% |
| 2002 Q2 | -2258.00 USD | 12.14% |
| 2001 Q2 | -601.00 USD | 87.13% |
| 2001 FY | -9269.00 USD | -31.07% |
| 2001 Q1 | -4671.00 USD | 53.29% |
| 2001 Q4 | -3236.00 USD | -325.23% |
| 2001 Q3 | -761.00 USD | -26.62% |
| 2000 Q4 | -10 Thousand USD | 0.0% |
| 2000 Q2 | -10 Thousand USD | 0.0% |
| 2000 FY | -7072.00 USD | 29.28% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 100.0% |
| 1999 FY | -10 Thousand USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q3 | - USD | 100.0% |
| 1999 Q2 | -10 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | 2612.295% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 615.321% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 2164.025% |
| CytoDyn Inc. | -18.05 Million USD | 119.603% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 106.001% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | 489855.261% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 294.9% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 170.176% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 11918.91% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 2050.574% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 136.474% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 106.377% |
| SQZ Biotechnologies Company | -75.82 Million USD | 104.669% |
| Resverlogix Corp. | -12.74 Million USD | 127.767% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 1008.694% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 63.664% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 244.177% |
| Mesoblast Limited | -84.14 Million USD | 104.207% |
| GB Sciences, Inc. | -1.42 Million USD | 349.206% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 615.321% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 119.835% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 203.965% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 153.249% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 211.733% |
| ContraFect Corporation | -56.88 Million USD | 106.223% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 228.688% |
| BioStem Technologies, Inc. | -7.77 Million USD | 145.507% |
| LadRx Corporation | -3.82 Million USD | 192.582% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 122.307% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 416.354% |
| CSL Limited | 3.7 Billion USD | 99.904% |
| Biomind Labs Inc. | -1 Million USD | 450.633% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 480.081% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 95.675% |
| Nascent Biotech, Inc. | -2.22 Million USD | 258.753% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 104.931% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 27.973% |
| GeneThera, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 330.461% |
| Marizyme, Inc. | -34.08 Million USD | 110.385% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 142.395% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 726.856% |
| Zenith Capital Corp. | -8.94 Million USD | 139.584% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 224.188% |
| Halberd Corporation | -75.05 Thousand USD | 4816.855% |
| Genus plc | 6.4 Million USD | 44.688% |
| Pharming Group N.V. | -4.87 Million USD | 172.548% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 278.205% |
| IMV Inc. | -38.67 Million USD | 109.154% |
| Affymax, Inc. | -15.04 Million USD | 123.528% |
| SYBLEU INC | -149.18 Thousand USD | 2472.972% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 439.08% |
| Enzolytics Inc. | -2.14 Million USD | 264.743% |
| argenx SE | -425.04 Million USD | 100.833% |
| AVAX Technologies, Inc. | 6.69 Million USD | 47.108% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 352.498% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 365.083% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 194.49% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 14164.362% |
| Cell Source, Inc. | -4.32 Million USD | 181.843% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 832.825% |
| Q BioMed Inc. | -3.44 Million USD | 202.739% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 183.522% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 381.847% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 234.728% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 177.721% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 106.44% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 222.016% |
| Rebus Holdings, Inc. | -664 Thousand USD | 633.133% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 459.737% |
| Skye Bioscience, Inc. | -13.67 Million USD | 125.893% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 289.876% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 276.58% |
| ONE Bio Corp. | 13.68 Million USD | 74.126% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 283.172% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 414.693% |
| Agentix Corp. | -1.37 Million USD | 358.063% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 221.256% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 324.142% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 20420.303% |
| Kadimastem Ltd | -3.04 Million USD | 216.438% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 1452.56% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 952.029% |
| NovAccess Global Inc. | -2.46 Million USD | 243.508% |
| Itoco Inc. | -919.14 Thousand USD | 485.143% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 1708.521% |
| Qrons Inc. | -643.67 Thousand USD | 649.965% |
| Mobile Lads Corp. | -554.55 Thousand USD | 738.355% |
| Genscript Biotech Corporation | -415.79 Million USD | 100.851% |
| International Stem Cell Corporation | -663 Thousand USD | 633.937% |
| Bioxytran, Inc. | -3.82 Million USD | 192.667% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 6824.924% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 17504.13% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 109.761% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 318.789% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 581.086% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 213.79% |
| Neutra Corp. | -229.48 Thousand USD | 1642.578% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 120.184% |
| PureTech Health plc | -146.19 Million USD | 102.421% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 116.472% |
| IXICO plc | -1.43 Million USD | 346.347% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 137.298% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 102.906% |
| CSL Limited | 3.81 Billion USD | 99.907% |
| Cellectis S.A. | -108.85 Million USD | 103.252% |